Important Safety Information
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy. The type and frequency of adverse events reported are consistent with events typically seen following surgery when used as directed. Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events. For important safety information, please see the package insert.
References
1. Becker JM, Dayton MT, Fazio VW, et al.
Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based
bioresorbable membrane: a prospective, randomized, double-blind multicenter
study. J Am Coll Surg 1996;183;297-306.
2. Diamond MP. Reduction of adhesions after uterine
myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized,
multicenter clinical study. Fert Steril 1996; 66(6);904-910.
3. Data on file, Genzyme Biosurgery.
|
Genzyme Corporate
If you are having abdominal or gynecologic surgery--such as 
Surgeons know the risks associated with adhesions--that’s why many of them rely on Seprafilm. They have applied more than 800,000 sheets since its introduction.3 Seprafilm is a proven adhesion barrier.1,2 With clinical trials in both the abdomen and pelvis, no adhesion barrier has been studied more broadly than Seprafilm.